ZEFER and H2ME deliver 100 hydrogen taxis to Copenhagen and achieve a key milestone for transport in Europe
21.4.2022 11:00:00 EEST | Business Wire | Press release
Two pan-European projects have collaborated to bring zero emission hydrogen taxis and a new hydrogen refuelling station to the Danish capital city.
The ZEFER (Zero Emission taxi Fleets for European Rollout) and H2ME2 (Hydrogen Mobility Europe) projects, both funded by Europe’s Clean Hydrogen Partnership1, have deployed 100 hydrogen taxis in Copenhagen with app-based taxi company DRIVR. The Toyota Mirais run on green hydrogen from renewable energy, following the installation and opening of a new hydrogen refuelling station (HRS) in the city.
This latest deployment of taxis means the wider ZEFER project has achieved its full complement of 180 FCEVs in high-utilisation, captive fleets across Europe with deployments in three capital cities (Paris, London and Copenhagen). The taxi deployment in Copenhagen will complement 60 taxis previously deployed to Hype by STEP in Paris, and 60 other passenger cars in London deployed between private-hire firm Green Tomato Cars (50) and the Metropolitan Police (10).
To date the 120 vehicles operated under the ZEFER project have driven over 7 million kilometres fuelled only by hydrogen. This high mileage is achieved as the project deliberately targets the very long daily mileage applications which are most suitable to hydrogen vehicles. They have achieved this without major safety or reliability incidents and vehicle performance has been rated highly by drivers and fleet managers, with limited breakdowns or issues encountered relating directly to the hydrogen drivetrain.
The Danish government have targeted all taxis to be zero emission by 2030 and DRIVR won the public tender to deliver ad-hoc taxi services in the City of Copenhagen. The 100 new hydrogen taxis will complement DRIVR's existing low emission fleet, already comprising hybrid, electric and hydrogen vehicles.
“We are incredibly proud that DRIVR has been entrusted with the important task of helping the municipality of Copenhagen reach its environmental goals, and we’re very grateful for the cooperation with Toyota, which has enabled us to meet their needs with the new Toyota Mirai hydrogen cars.” said Haydar Shaiwandi, CEO DRIVR.
“While aiming to deploy its platform in 15 new cities by 2024, Hype believes that hydrogen is one of the most relevant solutions for intensive and random mobility and that the taxi market can play a key role in accelerating the adoption of hydrogen by professionals at scale. We are glad to see DRIVR ramping up the integration of hydrogen among its solutions. This demonstrates that, thanks to the support of programmes such as ZEFER, an increasing number of players are taking the hydrogen path. Early adopters will definitely have an advantage and leverage their experience moving forward.” said Mathieu Gardies, President of Hype.
- Ends -
Notes to Editor
1 previously Fuel Cell and Hydrogen 2 Joint Undertaking (FCH2 JU)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005150/en/
Contact information
Declan Shepherd
info@zefer.eu
01509 642 500
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom